Company profile: Waverley Pharma
1.1 - Company Overview
Company description
- Provider of specialty pharmaceutical products.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Waverley Pharma
Ceptaris
HQ: United States
Website
- Description: Provider of a proprietary gel formulation of mechlorethamine hydrochloride under development for the treatment of early-stage (stages I–IIA) mycosis fungoides, a type of cutaneous T-cell lymphoma (CTCL); if approved, it would be the first topical treatment for this indication.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ceptaris company profile →
Valerio Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage oncology therapeutics leveraging the platON chemistry platform to generate DNA-decoy compounds targeting intracellular DNA-binding proteins for tumors and inflammatory diseases; develops AsiDNA and VIO-01 to disrupt DNA repair and activate the STING pathway, and Belinostat/Beleodaq, a histone deacetylase inhibitor for hematological and solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Valerio Therapeutics company profile →
Sapience Therapeutics
HQ: United States
Website
- Description: Provider of novel peptide therapeutics addressing major unmet medical needs, including ST101, a peptide antagonist targeting C/EBPβ in Phase 2 for advanced solid tumors such as recurrent GBM, and ST316, a first-in-class peptide antagonist of β-catenin entering Phase 1-2 for solid tumors with Wnt/β-catenin pathway abnormalities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sapience Therapeutics company profile →
Aptevo Therapeutics
HQ: United States
Website
- Description: Provider of bispecific immunotherapies and platform technologies for cancer treatment, focused on oncology and hematology. Portfolio includes ADAPTIR and ADAPTIR-FLEX platforms, plus candidates APVO436 (CD3xCD123, Phase 2 AML), APVO603 (4-1BB/OX40), APVO442 (PSMA/CD3 for prostate cancer), and APVO711 (PD-L1/CD40).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aptevo Therapeutics company profile →
Immunome
HQ: United States
Website
- Description: Provider of immunotherapy and antigen discovery solutions, developing targeted therapies including IM-4320 (IL-38-focused tumor control) and 177Lu-FAP radioligand for solid tumors aimed at enhanced tumor radiation delivery. Offers Memory B cell hybridoma technology, a Targeted Effector platform using small-molecule ligands for payload delivery and radioligand design, and the Immunome Discovery Engine to identify novel therapeutic targets and antibodies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunome company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Waverley Pharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Waverley Pharma
2.2 - Growth funds investing in similar companies to Waverley Pharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Waverley Pharma
4.2 - Public trading comparable groups for Waverley Pharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →